Hims & Hers Health, Inc.

NYSE:HIMS 株式レポート

時価総額:US$5.1b

Hims & Hers Health 配当と自社株買い

配当金 基準チェック /06

Hims & Hers Health配当金を支払った記録がありません。

主要情報

n/a

配当利回り

1.9%

バイバック利回り

総株主利回り1.9%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow

Nov 05

HIMS: GLP-1 Is Just The Beginning

Oct 17

Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward

Oct 03

Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce

Oct 01
Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce

Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now

Sep 24

Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)

Aug 27

Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade

Aug 20

Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Aug 11
Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage

Aug 07

Hims & Hers: The Thesis Goes Far Beyond GLP-1

Jul 18

Hims & Hers: Buy The Dip To Catch The Next Rip

Jun 24

Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Jun 19
Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Hims & Hers: The Undervalued Gem Poised For Growth

Jun 18

Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable

Jun 10

Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead

May 21

Hims & Hers Health: An Unforced Error

May 06

Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

May 04
Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry

Apr 24

Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation

Apr 05

Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock

Mar 21

Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health

Mar 12

Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%

Feb 28
Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%

Hims & Hers: Turning The Profitability Corner And Returning 28%

Feb 25

Hims & Hers Health: No Clear Moat Besides First Mover Advantage

Jan 23

Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple

Jan 10

Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)

Jan 07
Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers Health Q3: The Cheapest Growth Stock Around

Dec 14

Hims & Hers Health: What Would The Author Of 100 Baggers Say?

Nov 30

Hims & Hers: The Most Undervalued Small Cap Stock I See

Nov 08

Hims & Hers: A Promising Company With Resolvable Challenges

Nov 02

Hims & Hers: Specialization Is The Secret To Great Growth

Oct 25

Hims & Hers Health: Can't Get Much Better

Sep 25

The Market Is Wrong On Hims & Hers Health

Sep 18

Hims & Hers: The Current Weakness Creates A Buying Opportunity

Aug 15

決済の安定と成長

配当データの取得

安定した配当: HIMSの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: HIMSの配当金が増加しているかどうかを判断するにはデータが不十分です。


配当利回り対市場

Hims & Hers Health 配当利回り対市場
HIMS 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (HIMS)n/a
市場下位25% (US)1.4%
市場トップ25% (US)4.4%
業界平均 (Healthcare)1.6%
アナリスト予想 (HIMS) (最長3年)0%

注目すべき配当: HIMSは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: HIMSは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。


株主への利益配当

収益カバレッジ: HIMSの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。


株主配当金

キャッシュフローカバレッジ: HIMSが配当金を報告していないため、配当金の持続可能性を計算できません。


高配当企業の発掘